3,000
Participants
Start Date
May 9, 2025
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2025
Statement communicating uncertainty with a single arm trial
Because Zenova has not been compared to other treatments, it is unknown if Zenova is better, the same, or worse than other treatments for non-small cell lung cancer.
Statement communicating uncertainty with limited study duration
Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown.
Statement communicating uncertainty with a limited study population
Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.
Statement communicating uncertainty with an unvalidated surrogate endpoint
Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.
Statement communicating uncertainty with treatment effect size
It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.
RECRUITING
Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston
Harvard Medical School / Harvard Pilgrim Health Care Institute
UNKNOWN
London School of Economics and Political Science
OTHER